Research Applications for Striatech Products

Retinal Degeneration

Progressive, largely irreversible loss of photoreceptors, RPE, and retinal ganglion cells across inherited, age-related, toxic, ischaemic, and inflammatory contexts. A cross-cutting mechanistic theme rather than a single disease entity.
Introduction

What is Retinal Degeneration?

Retinal degeneration refers to the progressive loss of photoreceptors, retinal pigment epithelium (RPE) cells, or retinal ganglion cells (RGCs) accompanied by measurable decline in visual function. As a cellular mechanism it is not restricted to a single disease entity. Outer retinal pathology (characterised by photoreceptor apoptosis, RPE metabolic failure, or RPE-photoreceptor metabolic uncoupling) occurs in inherited retinal dystrophies, age-related macular degeneration (AMD) surrogates, chronic neuroinflammation, systemic neurodegenerative diseases, metabolic insults, and acute traumatic injury. For a comprehensive overview see Retinal Degeneration and Inherited Retinal Disease. This page focuses on retinal degeneration as a shared cellular mechanism across disease contexts, examining the specific molecular pathways, secondary outcome scenarios, and cross-disease functional measurement principles that span multiple application areas: Glaucoma and Optic Nerve Neurodegeneration, Neurodegenerative Disease, Neuroinflammation and Autoimmune CNS Disease, Ocular and CNS Toxicity Models, Ocular Inflammation and Immune-Mediated Eye Disease, Rare and Inherited CNS and Eye Disorders, Systemic Aging and CNS Decline, Trauma and Acute Injury, Vascular and Metabolic Disease, Neurodevelopment and Circuit Mechanisms and Maintaining and Restoring Vision.
Animal Models

What Are Common Animal Models For Retinal Degeneration?

The following models appear specifically in studies examining retinal degeneration as a mechanism across multiple disease contexts, as confirmed by the publications analysed for this cluster. Models relevant solely to the inherited retinal disease application area are covered on the Retinal Degeneration and Inherited Retinal Disease page.
  • Sodium iodate (NaIO3) mouse model: Systemic NaIO3 selectively ablates RPE cells, producing secondary photoreceptor degeneration that replicates the outer retinal atrophy of advanced dry AMD. The model is widely used across Ocular Toxicity and Systemic Aging contexts to establish RPE-specific degeneration mechanisms and to serve as a functional platform for RPE replacement therapies. (Carido et al., 2014, Invest. Ophthalmol. Vis. Sci.)
  • Soluble guanylate cyclase-deficient mice (sGC knockout): Disruption of the NO-sGC-cGMP signalling axis produces progressive, age-compounded RGC degeneration and outer retinal pathology with features of both glaucomatous and inherited retinal degeneration. OptoDrum longitudinal visual acuity profiles reveal an age-dependent functional decline trajectory spanning multiple disease contexts. (Bossardet et al., 2026, Sci. Rep.)
  • Rod-specific VPS35-knockout mice: Photoreceptor-specific deletion of the Parkinson's disease gene VPS35 produces progressive rod-dominant retinal degeneration with neuroinflammatory infiltration and RGC death, directly linking a systemic neurodegeneration gene to outer retinal pathology. Dual OptoDrum (photopic) and ScotopicKit (scotopic) profiling uniquely resolves rod- and cone-mediated functional decline. (Fu et al., 2024, Nat. Commun.)
  • Mitochondrial complex I-deficient mice: Rare inherited complex I deficiency replicates the retinal metabolic toxicity produced by pharmacological complex I inhibitors (rotenone, MPTP), enabling mechanistic overlap between genetic mitochondrial disease and neurotoxicological paradigms. Progressive retinal degeneration is detectable by non-invasive optomotor testing. (Avrutsky et al., 2022, Transl. Vis. Sci. Technol.)
  • 5xFAD and related amyloid-beta overexpression mice (Alzheimer's disease models): Retinal amyloid-beta accumulation and impaired clearance in Alzheimer's disease models produces secondary RGC dysfunction and outer retinal thinning, with optomotor-measured visual acuity serving as a non-invasive functional correlate of retinal amyloid burden. (Sheng et al., 2026, Invest. Ophthalmol. Vis. Sci.; Matynia et al., 2024, Invest. Ophthalmol. Vis. Sci.)
  • CLN1/PPT1-deficient mice (infantile neuronal ceroid lipofuscinosis): Batten disease (CLN1) is driven by lysosomal dysfunction and neuroinflammation; retinal degeneration is a secondary consequence of the same inflammatory cascade that destroys cortical neurons. OptoDrum enables non-invasive longitudinal functional monitoring across both retinal and CNS disease endpoints without requiring terminal tissue collection. (Groh et al., 2021, Brain Commun.)
  • Inflammatory retinopathy / streptozotocin (STZ) diabetic retinopathy models: Models of neuroinflammatory and vascular retinopathy with metabolic drivers (including diabetic conditions) produce progressive retinal neurodegeneration with measurable optomotor deficits; immunomodulatory intervention studies in these models demonstrate that the inflammatory component of retinal degeneration is a cross-disease therapeutic target. (Kinuthia et al., 2025, JCI Insight)
Research Questions

How Can Striatech Tools support Your Study?

Select a question that matches your research objective to see which instruments are relevant, what challenge they address, and what the published evidence shows.
01
How Does RPE Metabolic Dysfunction Produce Outer Retinal Degeneration, and How Do Striatech Tools Characterise This Mechanism Across Disease Models?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

The RPE maintains photoreceptor survival through a bidirectional metabolic co-dependency: photoreceptors consume glucose and produce lactate; RPE cells export lactate via monocarboxylate transporters (MCTs) and recycle metabolites back to photoreceptors. When RPE function is disrupted – by selective chemical ablation (NaIO3), MCT deficiency, lipid metabolism failure, or oxidative stress – photoreceptor outer segments degenerate secondarily. OptoDrum measures the functional consequence of this metabolic uncoupling as a progressive, quantifiable decline in optomotor-measured spatial visual acuity, providing a non-invasive in vivo endpoint that spans AMD surrogate models, rare metabolic dystrophies, and toxicological platforms.

The challenge

The RPE-photoreceptor metabolic axis is a disease-relevant mechanism shared across inherited retinal dystrophies (e.g., MCT2 deficiency), AMD, and chemical RPE ablation models. Yet functional endpoints for RPE metabolic integrity remain predominantly histological or electrophysiological (ERG a-wave amplitude), requiring substantial expertise and often terminal tissue collection. Researchers working across the Ocular Toxicity, Systemic Aging, and Rare Disease contexts need a standardised, non-invasive functional readout that documents the time course and magnitude of outer retinal degeneration in these mechanistically distinct models – and that can serve as the primary efficacy endpoint for RPE-directed therapies.

Sodium iodate injection is the most widely used rapid RPE ablation paradigm, but its functional characterisation – determining when and by how much visual acuity declines after RPE loss – is required to use it as a platform for evaluating repair or neuroprotection strategies. Similarly, rare inherited MCT deficiency models require functional baselines to demonstrate that gene therapy has achieved physiologically meaningful photoreceptor rescue rather than mere structural preservation.

How Striatech products help

OptoDrum

Measures photopic spatial visual acuity (cycles per degree) and contrast sensitivity via the subcortical optomotor reflex in awake, freely moving rodents. Provides the time course of outer retinal functional decline following RPE ablation or metabolic failure, and serves as the primary in vivo efficacy endpoint for RPE-targeted gene therapies and metabolic rescue strategies.

ScotopicKit

Extends OptoDrum testing to dark-adapted, scotopic conditions to detect rod photoreceptor-specific function. Relevant for distinguishing RPE-driven rod loss from cone-dominant degeneration and for evaluating rod-targeting therapeutic strategies in RPE metabolic disease models.

DarkAdapt

Provides a light-tight, controlled dark-adaptation environment for rodents prior to scotopic OMR testing, ensuring consistent scotopic baseline conditions across longitudinal study timepoints.

Non-aversive Animal Platform

Minimises handling stress during testing of animals that may be debilitated by advanced retinal degeneration or post-surgical recovery from gene therapy delivery procedures.

AcuiSee

Measures cortical visual acuity via an operant visual-reward paradigm. Applicable where RPE metabolic dysfunction is known or suspected to produce visual processing deficits that extend beyond the retino-brainstem pathway to cortical representation – for example in systemic metabolic disease models with multi-level CNS involvement.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Carido et al (2014) IOVS

    Established the foundational OptoDrum-based functional characterisation of NaIO3-induced RPE ablation. Demonstrated a progressive, quantifiable decline in optomotor visual acuity following selective RPE loss, mapping the functional timeline against which all subsequent RPE replacement and neuroprotection studies in this model must be benchmarked.

  • Chandler et al (2025) Proc Natl Acad Sci U S A.
    Journal Club →
    Feature →

    Demonstrated that AAV-mediated RPE-specific overexpression of monocarboxylate transporter 2 (MCT2) preserves photoreceptor viability and visual function in an inherited retinal dystrophy driven by RPE metabolic failure. OptoDrum confirmed that restoring lactate transport in the RPE translates to a behaviourally meaningful preservation of spatial visual acuity, validating the RPE metabolic axis as a gene therapy target.

02
How Can Optomotor Testing Detect Retinal Degeneration as a Secondary Outcome When the Primary Disease Is Systemic or Neurological?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Retinal degeneration occurs as a secondary feature in a diverse range of systemic and CNS diseases – including Alzheimer’s disease, Parkinson’s disease, signalling pathway deficiencies, and rare inherited metabolic disorders – often before the primary CNS pathology is detectable by conventional endpoints. OptoDrum provides a non-invasive, repeatable, subcortical optomotor readout that documents this retinal involvement quantitatively, enabling researchers whose primary interest is not ocular to use visual function as an accessible disease severity biomarker without requiring terminal ocular histology at each timepoint.

The challenge

Researchers working in the Neurodegenerative Disease, Systemic Aging, Glaucoma, and Rare and Inherited CNS Disease application areas frequently encounter retinal degeneration as a secondary phenotype. Confirming that the retina is affected – and quantifying the degree of functional impairment – typically requires ERG, histology, or optical coherence tomography (OCT), all of which are resource-intensive and not easily scaled for longitudinal time-course studies. Moreover, interpreting functional visual readouts in models where the disease affects multiple retinal cell types requires distinguishing which cell class is most vulnerable: photoreceptors (outer retina), RGCs (inner retina), or both.

For example, sGC deficiency disrupts the NO-cGMP pathway shared between trabecular meshwork and RGCs, producing both raised intraocular pressure and direct RGC metabolic impairment – making it simultaneously a glaucoma model and an inherited retinal degeneration model. Similarly, in Alzheimer’s disease models, retinal amyloid deposition activates the same microglial complement cascades that drive cortical neuroinflammation, producing RGC dysfunction that can be tracked non-invasively by OptoDrum even when cognitive tests are not yet sensitive to the early disease stage. For the specific context of Alzheimer’s retinal involvement and Neurodegenerative Disease more broadly, including tau and amyloid biomarker strategies, see the relevant parent pages.

How Striatech products help

OptoDrum

Measures subcortical optomotor spatial acuity and contrast sensitivity non-invasively in awake rodents. In cross-context retinal degeneration studies, it provides the functional correlate of retinal structural findings (RGC counts, OCT measurements) without requiring terminal tissue collection at each timepoint, making it practical for longitudinal disease monitoring in systemic disease models.

ScotopicKit

Resolves rod-specific degeneration from cone or inner retinal dysfunction. In Parkinson’s disease gene models (rod-specific VPS35 knockout), scotopic OMR distinguishes rod-photoreceptor-specific degeneration from cone loss, providing cell-type resolution that is unavailable from conventional white-light optomotor testing alone.

DarkAdapt

Provides controlled dark adaptation for scotopic OMR testing in longitudinal disease models.

Non-aversive Animal Platform

Reduces handling stress for aged or systemically compromised animals, relevant for aging and neurodegenerative disease longitudinal cohorts.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Bossardet et al (2026) Sci Rep.

    Demonstrated that sGC deficiency produces progressive, age-compounded retinal degeneration and RGC loss with measurable visual acuity decline tracked by OptoDrum across multiple age groups. A mechanistically defined cross-pillar model: sGC disrupts the NO-cGMP axis shared by trabecular meshwork and RGC populations, producing retinal degeneration as a secondary consequence of a signalling pathway deficiency.

  • Fu et al (2024) Nat Commun.

    Rod photoreceptor-specific deletion of the Parkinson’s disease retromer gene VPS35 produced progressive retinal degeneration with neuroinflammatory infiltration and RGC death. Both photopic (OptoDrum) and scotopic (ScotopicKit) visual function were measured, with scotopic deficits preceding photopic changes – demonstrating that dual-modality testing resolves the rod-specific degeneration driven by a systemic neurodegeneration gene.

  • Sheng et al (2026) Invest Ophthalmol Vis Sci.

    Linked impaired retinal amyloid-beta clearance in an Alzheimer’s disease model to secondary retinal degeneration, RGC dysfunction, and neuroinflammatory changes, with OptoDrum providing the non-invasive functional endpoint. This study positions retinal amyloid burden and its functional correlate as an accessible surrogate readout for the broader CNS amyloid pathology of Alzheimer’s disease.

  • Matynia et al (2024) Invest Ophthalmol Vis Sci.
    Journal Club →
    Feature →

    Investigated differential RGC subtype vulnerability in Alzheimer’s disease models, documenting that ipRGCs are partially preserved while other RGC populations degenerate – with optomotor acuity providing the in vivo functional correlate of selective RGC loss. This calibration of functional-to-histological correspondence in AD-associated retinal degeneration is essential for interpreting OptoDrum-data at different disease stages.

  • Liu et al (2024) Brain.

    Characterised PNPLA6/NTE deficiency – the gene responsible for Gordon Holmes and Oliver McFarlane syndromes – in a mouse model, documenting progressive optic nerve damage, retinal dystrophy, and visual function decline measured by OptoDrum. An example of a rare systemic lipid metabolism disorder in which retinal degeneration is a secondary but clinically significant phenotype.

03
How Does Neuroinflammation Amplify Retinal Degeneration in Non-Retinal Disease Contexts, and Can Striatech Tools Track the Functional Consequence?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Microglial activation, cytokine release, and complement cascade engagement drive photoreceptor and RGC loss in inherited retinal dystrophies, aging-associated AMD, CLN1 Batten disease, epigenetically dysregulated inflammatory retinopathy, and systemically inflamed aging models. OptoDrum documents the functional visual consequence of this inflammatory amplification non-invasively and longitudinally, enabling researchers to test whether anti-neuroinflammatory interventions – from microglial depletion to PROTAC-mediated epigenetic reprogramming – translate to circuit-level visual preservation across disease contexts.

The challenge

Neuroinflammation is a recognised amplifier of photoreceptor degeneration in multiple disease contexts that span several parent application areas. In inherited retinal dystrophies, secondary microglial activation accelerates primary photoreceptor death beyond what the genetic lesion alone would produce. In systemic aging (“inflammaging”), chronic low-grade proinflammatory signalling drives outer retinal thinning in the absence of a primary ocular genetic defect. In rare lysosomal storage disorders such as CLN1 Batten disease, the same neuroinflammatory cascade that destroys cortical neurons also degrades the retina – providing a tractable, non-invasive functional endpoint via OptoDrum that avoids the ethical and logistical burden of frequent cortical tissue collection.

The challenge for researchers across these contexts is that microglia are not uniformly damaging. Karg et al. demonstrated that certain microglial states in aged mice are neuroprotective and that their dysfunction accelerates, rather than alleviates, retinal degeneration – a critical nuance for indiscriminate microglial depletion strategies. Any neuroinflammation-targeting intervention study therefore requires a sensitive, longitudinal visual function endpoint capable of distinguishing protective microglial modulation from damaging activation. For the broader neuroinflammatory disease context, see Neuroinflammation and Autoimmune CNS Disease and Ocular Inflammation and Immune-Mediated Eye Disease.

How Striatech products help

OptoDrum

Provides longitudinal, non-invasive visual acuity and contrast sensitivity monitoring across disease progression and treatment timecourses. In neuroinflammatory models, repeated OptoDrum measurements track whether anti-inflammatory intervention translates to functional visual preservation, replacing or complementing terminal histological microglial/photoreceptor counts at each timepoint.

Non-aversive Animal Platform

Reduces corticosterone-mediated confounds in stress-sensitive neuroinflammation models, where stress hormones can modulate microglial activation state independently of the experimental treatment.

DarkAdapt

Provides controlled dark adaptation for scotopic testing in models where neuroinflammation differentially affects rod versus cone photoreceptors.

ScotopicKit

Resolves rod-specific neuroinflammatory photoreceptor loss from cone or inner retinal dysfunction, relevant for microglial activation studies in rod-dominant retinal dystrophies.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Groh et al (2021) Brain Commun.
    Journal Club →

    Demonstrated that immune modulation attenuates CLN1 Batten disease progression, a rare neuroinflammatory lysosomal storage disorder, using OptoDrum as a non-invasive longitudinal biomarker of both disease progression and treatment response.

  • Hollingsworth et al (2022) Front. Pharmacol.
    Journal Club →

    Documented that chronic systemic proinflammatory exposure (modelling aging-associated inflammaging) accelerates retinal degeneration and visual function decline, with OptoDrum capturing this acceleration longitudinally. The study demonstrates that systemic inflammatory tone drives outer retinal pathology independently of any primary ocular genetic lesion – a mechanistic link between systemic aging, neuroinflammation, and retinal degeneration.

  • Zhu et al (2023) J. Neuroinflammation

    Demonstrated that PROTAC-mediated degradation of BET bromodomain proteins – master epigenetic regulators of inflammatory gene programmes – suppresses neuroinflammation and protects retinal function in an inflammatory retinal disease model. OptoDrum confirmed that this epigenetic anti-inflammatory approach preserved optomotor visual acuity, validating a novel drug class for neuroinflammatory retinal degeneration.

  • Karg et al (2023) Immun Ageing.
    Journal Club →
    Feature →

    Demonstrated the neuroprotective – rather than uniformly damaging – role of microglia in aging-associated retinal degeneration, showing that microglial dysfunction worsens visual outcomes rather than blunt depletion improving them. OptoDrum tracked the functional consequences of microglial modulation across aging timepoints, providing a critical nuance for therapeutic targeting strategies in aging retinal research.

  • Shi et al (2024) Int Immunopharmacol.

    Showed that minocycline, acting via microglial activation suppression, preserved visual acuity and contrast sensitivity in inherited retinal dystrophy. This positions anti-microglial pharmacology – relevant across inherited dystrophy, neuroinflammatory, and aging retinal degeneration contexts – as having a measurable, OptoDrum-detectable functional benefit.

04
How Does the Functional Therapeutic Window Differ Across Retinal Degeneration Contexts, and How Do Striatech Tools Define It?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

The therapeutic window – the period during which the retinal circuit retains sufficient surviving photoreceptors or inner retinal neurons to produce a functional response to intervention – varies substantially across genetic, acquired, and secondary retinal degeneration models and is not predictable from structural data alone. OptoDrum provides a non-invasive, longitudinal functional staging tool that defines when visual function first becomes impaired, how rapidly it declines, and at what point it falls below the detection threshold – information that is essential for selecting the appropriate intervention timepoint, designing adequately powered therapeutic studies, and demonstrating functional rescue above the degeneration trajectory.

The challenge

In genetic models such as rd1, rod degeneration is near-complete by postnatal day 21, leaving an extremely narrow window for rod-targeted interventions. In slower-progressing models (rd10, P23H, sGC deficiency, CLN1), functional stages can span weeks to months, but the relationship between structural photoreceptor count and functional OptoDrum acuity is non-linear: partial photoreceptor preservation may sustain near-normal OMR until a critical threshold is crossed. Stage-dependent profiling with OptoDrum identifies this threshold and distinguishes the biologically productive intervention window from stages at which only inner-retinal bypass strategies (bipolar cell optogenetics, AAV-delivered inner retinal opsins, cell transplantation) can restore function.

Additionally, translational studies require demonstrating that a preclinical vector formulation, delivery route, or dosing regimen achieves a functionally meaningful benefit – not merely structural preservation as determined by histology. OptoDrum and, in rod-dominant disease, ScotopicKit provide this quantitative functional efficacy anchor, allowing researchers to establish dose-response relationships and to compare clinical-grade versus research-grade vector preparations on a functional basis. For therapeutic restoration strategies in depth, see Maintaining and Restoring Vision. For trauma-related neuroprotection windows, see Trauma and Acute Injury.

How Striatech products help

OptoDrum

Provides repeated, non-invasive spatial visual acuity and contrast sensitivity measurements at multiple disease stages to define the functional trajectory and therapeutic window. Enables functional dose-response curves for vector-based therapies and confirms that a given intervention produces OptoDrum-measurable benefit above the untreated degeneration trajectory.

ScotopicKit

Resolves rod-specific functional preservation from mixed-pathway responses; essential for rod-targeted neuroprotection and gene therapy studies where cone function may be partially maintained even when the therapeutic question concerns rod rescue. Confirmed dual-modality use in Brunet et al. (2026) and Fu et al. (2024).

DarkAdapt

Ensures reproducible dark adaptation prior to scotopic OMR testing across longitudinal timepoints, a prerequisite for comparing within-subject rod function across the therapeutic study timeline.

Non-aversive Animal Platform

Reduces handling stress in post-surgical animals (gene therapy delivery, subretinal injection recovery) and in highly degenerated animals with reduced sensory robustness, ensuring that stress-related variability does not confound therapeutic window estimates.

AcuiSee

Measures cortical visual acuity via an operant paradigm; relevant for assessing whether restoration of photoreceptor or inner retinal function translates to higher-order cortical visual representation, complementing the subcortical OptoDrum endpoint in cell transplantation or advanced optogenetics studies.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Cha et al (2022) Front. Cell. Neurosci.

    Provided the empirical framework for stage-dependent functional profiling of inherited retinal degeneration, mapping spatial visual acuity and contrast sensitivity from early photoreceptor loss through functional blindness. Defines the stages at which OptoDrum measurements are most sensitive and identifies when function becomes irreversibly impaired. This calibration is applicable across any retinal degeneration model where a therapeutic window must be defined.

  • Brunet et al (2026) Biomedicines.

    Demonstrated AKT pathway activation as a rod photoreceptor neuroprotection strategy, using both OptoDrum (photopic) and ScotopicKit (scotopic) to provide an independent rod- and cone-functional profile of photoreceptor rescue. This is the only corpus publication to use both instruments in a therapeutic study, establishing the dual-modality design as best practice for rod-targeting therapeutic research where cone function is partially maintained.

  • Kralik et al (2022) Commun. Biol.

    Showed that targeting optogenetic tools to bipolar cells – which survive longer than photoreceptors in advanced degeneration – extends the functional therapeutic window for optogenetic vision restoration beyond the stage at which photoreceptors are viable targets. OptoDrum confirmed that bipolar cell targeting produced behaviourally measurable functional benefit in the post-photoreceptor-loss stage, demonstrating that inner retinal circuit integrity can compensate for photoreceptor loss in the functional readout.

  • Procyk et al (2025) Stem Cell Reports.
    Journal Club →
    Feature →

    Conducted human cone photoreceptor transplantation into a degenerated rodent retina and used OptoDrum photopic visual acuity as the primary functional readout confirming that transplanted human cones survived, integrated, and supported a behaviourally meaningful visual response.

  • Presa et al (2025) Commun Med (Lond).
    Journal Club →

    Used OptoDrum to confirm that a clinical-grade AAV vector preserves visual acuity in a preclinical retinal degeneration model at a level comparable to a research-grade preparation, providing a functional equivalence endpoint for IND-enabling preclinical studies. Demonstrates that OptoDrum-measured functional benefit is a sufficient functional anchor for translational vector comparability studies.

  • Benkner et al (2013) Behav. Neurosci.
    Journal Club →

    Established foundational visual acuity and contrast sensitivity profiles for rd1 and rd10 mice using the optomotor paradigm, spanning the full dynamic range from near-normal early function through near-complete functional loss. This reference baseline is required to interpret any subsequent therapeutic intervention study in these models – defining the pre-therapeutic trajectory against which rescue must be measured.

  • Pakian et al (2025) Mol Pharm.

    Evaluated a mucoadhesive topical ophthalmic formulation for posterior segment drug delivery in a retinal degeneration model, using OptoDrum visual acuity as the in vivo functional readout for both formulation tolerability and drug efficacy.

  • Hulliger et al (2020) Mol. Ther. Methods Clin. Dev.
    Journal Club →

    Identified and validated a bipolar-cell-specific promoter for optogenetic transgene delivery, with OptoDrum confirming that targeted bipolar cell expression restores a measurable optomotor response in blind mice after photoreceptor loss.

  • Lu et al (2024) Gene Ther
    Feature →

    Characterised the dose-response relationship between AAV vector dose and OptoDrum-measured visual function restoration in an optogenetics gene therapy paradigm, showing that only doses above a threshold level produce a behaviourally meaningful optomotor improvement. The resulting functional dose-efficacy curve directly informs translational vector dose selection for retinal gene therapy programmes.

  • Lin et al (2022) Biomater. Sci.

    Demonstrated that sustained-release in situ-crosslinked hydrogel drug delivery preserved functional visual acuity in a glaucoma model as measured by OptoDrum. Relevant as an example of a biomaterials drug delivery approach in which OptoDrum provides the translational functional endpoint for neuroprotective efficacy in glaucomatous retinal degeneration, complementing the mucoadhesive delivery study above.

  • Maddalena et al (2023) Front. Drug Deliv.

    Developed a CRISPR-mediated approach to drive cell-type-specific optogenetic transgene expression in retinal cells after photoreceptor loss, with OptoDrum confirming that precision-targeted optogenetic expression restores functional visual acuity in a degenerated retina. Represents the next generation of optogenetic delivery precision beyond simple AAV vector administration.

05
What Functional Readouts Does OptoDrum Provide for Retinal Degeneration Induced by Metabolic, Toxicological, and Vascular Insults?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Retinal degeneration produced by metabolic insults (mitochondrial complex I inhibition), ocular toxins (NaIO3), or vascular-inflammatory retinopathy (inflammatory DR models) shares a common feature: photoreceptor and RGC loss that produces a quantifiable optomotor deficit. OptoDrum captures this functional deficit as a non-invasive endpoint across all three categories, enabling researchers in the Ocular Toxicity, Vascular and Metabolic Disease, and Rare Disease application areas to use visual function as an in vivo safety, progression, or treatment efficacy readout without requiring terminal retinal histology at each study timepoint.

The challenge

Mitochondrial complex I dysfunction – whether genetic (NDUFS4 deficiency, modelling Leigh syndrome and LHON-related retinopathy) or pharmacological (rotenone, MPTP) – produces progressive outer retinal metabolic failure and photoreceptor degeneration. The visual functional consequences of this metabolic insult are detectable non-invasively by optomotor testing before they are apparent from ERG a-wave changes alone, and OptoDrum provides a practical, non-terminal platform for longitudinal monitoring in these models. Researchers in neurotoxicology using complex I inhibitor paradigms can apply the same functional endpoint used in the genetic model to validate their pharmacological preparations.

In vascular and inflammatory retinopathy models – including those with features of diabetic retinopathy – neuroinflammation and blood-retinal barrier breakdown drive progressive inner and outer retinal neurodegeneration that reduces optomotor performance. OptoDrum captures this functional deficit and can monitor the effect of immunomodulatory or vascular-protective interventions longitudinally. For the broader diabetic retinopathy context, see Diabetic Retinopathy and Vascular and Metabolic Disease.

How Striatech products help

OptoDrum

Provides a non-invasive, repeatable functional safety and efficacy readout for metabolic, toxicological, and vascular retinal degeneration models. Detects progressive outer retinal functional decline due to complex I deficiency, RPE ablation, or vascular neuroinflammation, serving as both a disease severity biomarker and an interventional efficacy endpoint.

Non-aversive Animal Platform

Reduces handling stress in debilitated animals (post-toxin treatment, metabolic disease, or post-surgical recovery from drug delivery procedures), minimising variability from stress-induced pupil dilation or corticosterone elevation that could confound contrast sensitivity measurements.

DarkAdapt

Enables scotopic OMR testing for conditions where rod-photoreceptor-specific sensitivity is preferentially affected by metabolic or vascular insults, such as mitochondrial disease or early diabetic retinopathy.

ScotopicKit

Extends OptoDrum to the scotopic domain for measuring rod photoreceptor functional integrity in metabolic and toxic retinal degeneration models, enabling earlier detection of rod-specific deficits prior to cone involvement.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Avrutsky et al (2022) Transl. Vis. Sci. Technol.

    Characterised visual function and retinal degeneration in a mouse model of mitochondrial complex I deficiency using a non-invasive ophthalmological test battery including OptoDrum-based visual acuity.

  • Kinuthia et al (2025) JCI Insight.

    Demonstrated that immunomodulatory treatment preserves visual function in inflammatory retinopathy with metabolic/vascular overlap, using OptoDrum to confirm that modulating the retinal immune environment translates to preserved optomotor performance in a retinopathy paradigm with diabetic retinopathy features.

  • Eghbali et al (2023) Cell J.

    Demonstrated that EPO protects RGCs and the optic nerve from degeneration following acute injury, partly by suppressing reactive glial neuroinflammation. OptoDrum confirmed that EPO-mediated neuroprotection translates to preserved visual circuit performance, bridging the acute injury and retinal degeneration mechanisms.

Product Fit

Summary: Striatech Products supporting your research questions

Research Question OptoDrum ScotopicKit AcuiSee Photorefractor Keratometer DarkAdapt Non-aversive platform
RPE metabolic axis Yes Yes Yes Yes
Secondary RD in CNS disease Yes Yes Yes Yes Yes
Neuroinflammation-RD axis Yes Yes Yes Yes
Therapeutic window Yes Yes Yes Yes Yes
Toxin and vascular RD Yes Yes Yes Yes
Measurement Modalities

Measuring Functional Visual Outcomes in Retinal Degeneration: How Do Available Methods Compare?

Modality Invasiveness Repeatability Automation 3Rs impact Best suited for
OptoDrum (subcortical OMR) None High – weekly or more frequent in the same animal Fully automated Reduces terminal timepoints; extends longitudinal cohorts Retino-brainstem pathway integrity; photoreceptor and inner retinal function across all degeneration contexts
ERG (electroretinography) Low-moderate (anaesthesia, corneal contact) Moderate – recovery time required between sessions Semi-automated Moderate – requires anaesthesia Photoreceptor-specific (a-wave) and inner retinal (b-wave) signals; direct photoreceptor layer assessment
VEP (visual evoked potential) Moderate (electrode implantation or skull screws) Moderate Partially automated Surgical implantation required Cortical visual pathway integrity; not specific to retina
OCT (optical coherence tomography) Low-moderate (anaesthesia, pupil dilation) High Semi-automated Moderate Structural retinal layer thickness; outer nuclear layer and RPE measurement
Histology / immunohistochemistry Terminal None – cross-sectional only Manual Terminal tissue collection required at each timepoint Photoreceptor counts, microglial activation state, cell-type-specific markers
AcuiSee (cortical operant) None High Automated operant paradigm Minimal Cortical visual discrimination; suprathreshold visual perception in CNS disease models with cortical involvement
OptoDrum and AcuiSee are complementary rather than competing: OptoDrum targets the retino-brainstem OMR pathway and is appropriate for detecting retinal and optic nerve pathway dysfunction, while AcuiSee targets cortical visual processing and is indicated when the research question concerns suprathreshold perception or cortical representation. ERG and OCT provide structural and electrophysiological specificity that OMR-based functional testing cannot fully replace, particularly for dissecting photoreceptor subclass contributions. For a comprehensive view of retinal degeneration measurement approaches in the inherited disease context, see Retinal Degeneration and Inherited Retinal Disease.
Supported by Striatech Products

Publications on Retinal Degeneration

Great Research, Interactive

Journal Clubs related to Retinal Degeneration

Featured image for “Journal Club: Photoreceptor Cell Therapy to Treat Advanced Retinal Degeneration”
Register to Watch Now
Thursday, 05 Feb 2026

Journal Club: Photoreceptor Cell Therapy to Treat Advanced Retinal Degeneration

Image
Rachael Pearson, Ph.D. - Ocular Cell and Gene Therapy Group, Centre for Gene Therapy and Regenerative Medicine, King’s College London
Image
This Journal Club highlights research by Rachael Pearson et al. on photoreceptor transplantation. Photoreceptor transplantation has long been proposed as a strategy to restore vision, but in advanced retinal degeneration it remained unclear whether the inner retinal neurons could still accept and process new inputs from donor cells. The study shows that human pluripotent stem cell–derived cone photoreceptors can integrate into end-stage mouse retinas, drive retinal function, and induce behavioral responses, revealing that even severely degenerated retinas retain the capacity to remodel in response to healthy photoreceptors.
Featured image for “Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision”
Q&A available
Register to Watch Now
Thursday, 11 Dec 2025

Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision

Image
Constance Cepko, Ph.D. - Harvard Medical School: Genetics & Ophthalmology (Blavatnik Institute) • HHMI
Image
This Journal Club features innovative research by Harvard’s Cepko lab, exploring gene-independent strategies to preserve vision in retinitis pigmentosa and other genetic forms of blindness. Using AAVs to enhance metabolic support, including MCT2 expression in retinal pigment epithelial cells, they preserved cone photoreceptors and maintained color and daylight vision across diverse genotypes.
Featured image for “Journal Club: RIP1 Inhibition Protects Retinal Ganglion Cells in Preclinical Glaucoma Models”
Q&A available
Watch now
Wednesday, 18 Jun 2025

Journal Club: RIP1 Inhibition Protects Retinal Ganglion Cells in Preclinical Glaucoma Models

Image
Bo Kyoung Kim, Ph.D. - Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.
Image
This Journal Club features innovative research by Kim et al., who revealed that inhibiting RIP1 kinase protects retinal ganglion cells in preclinical glaucoma models. Their work demonstrates that targeting necroptosis and inflammation can prevent cell loss and functional decline, directly linking genetic risk to inflammatory degeneration and highlighting RIP1 as a promising therapeutic target for neuroprotection in glaucoma.
Featured image for “Journal Club: The Impact of Lateral Inhibition on Healthy Vision and Retinal Degeneration”
Q&A available
Watch now
Thursday, 05 Dec 2024

Journal Club: The Impact of Lateral Inhibition on Healthy Vision and Retinal Degeneration

Image
Matteo Rizzi, Ph.D. - UCL Institute of Ophthalmology – Moorfields Eye Hospital, Visual Perception and Repair Laboratory
Image
This Journal Club provides insights into Matteo Rizzi’s research on lateral inhibition in the retina, highlighting its impact on visual function and the development of gene therapy for age-related macular degeneration.
Featured image for “Symposium: Opportunities, Hopes, and Challenges in Translating Visual Restoration from Mouse to Human”
Watch now
Sunday, 17 Sep 2023

Symposium: Opportunities, Hopes, and Challenges in Translating Visual Restoration from Mouse to Human

Image
Professor Eberhart Zrenner - Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen
Image
Image
Constance Cepko, PhD - Harvard Medical School
Image
Image
Miikka Terho, MBA - Pioneer Retina Implant Patient, Finland
Striatech celebrates its 5th anniversary with a top-class Symposium on the topic of translating visual restoration from mouse to human. Presentations will be given by Professor Eberhart Zrenner (University of Tübingen), Professor Constance Cepko (Harvard Medical School) and Miikka Terho (Pioneer Retina Implant Patient, Finland). In addition, the speakers will highlight important aspects and directions in this area of research in a moderated panel discussion.
Featured image for “Journal Club: Postsynaptic Neuronal Activity Promotes Retinal Axon Regeneration”
Q&A available
Watch now
Wednesday, 21 Jun 2023

Journal Club: Postsynaptic Neuronal Activity Promotes Retinal Axon Regeneration

Image
Supraja Varadarajan, Ph.D. - Stanford University, School of Medicine, Huberman Lab
Image
This Journal Club provides insights into mechanisms that promote retinal ganglion cell (RGC) axon regeneration in vertebrates after optic nerve injury.
Featured image for “Journal Club: Inherited Retinal Dystrophy: Chronic Proinflammatory Signaling Accelerates the Rate of Degeneration”
Q&A available
Watch now
Wednesday, 05 Apr 2023

Journal Club: Inherited Retinal Dystrophy: Chronic Proinflammatory Signaling Accelerates the Rate of Degeneration

Image
T.J. Hollingsworth, PhD - University of Tennessee Health Science Center
Image
T.J. Hollingsworth presents his work where he characterized a new polygenic mouse model of inherited retinal dystrophies, the BXD32 mouse strain. He presents evidence that a proinflammatory environment in the retina supports and accelerates the degeneration of the retina and the loss of visual function.
Featured image for “Webinar: AcuiSee – Rodent Visual Acuity Using Behavioral Conditioning”
Watch now
Wednesday, 17 Nov 2021

Webinar: AcuiSee – Rodent Visual Acuity Using Behavioral Conditioning

Image
Dr. Jeffrey A Jamison - Experimentica Ltd.
Image
In this Webinar, Dr. Jeff Jamison will talk about “AcuiSee”, with which one can measure rodent vision based on an operant conditioning paradigm. Jeff is the developer of AcuiSee, and he now works as Director of In-Vivo Pharmacology at Experimentica.
Featured image for “Journal Club: Restoring vision – Optogenetic gene therapy targeted at human ON-bipolar cells”
Q&A available
Watch now
Thursday, 25 Mar 2021

Journal Club: Restoring vision – Optogenetic gene therapy targeted at human ON-bipolar cells

Image
Dr. Elmar Hulliger - Institute of Physiology, University of Bern
Image
Optogenetic gene therapy holds great promise for healing blindness. Hulliger et al have developed a new promoter that effectively targets human ON bipolar cells. This is an important step towards clinical applications of optogenetic gene therapy for restoring vision.
Featured image for “Webinar: Visual Acuity as a Relevant Phenotype in Mouse Models of Rare Disease”
Watch now
Thursday, 08 Oct 2020

Webinar: Visual Acuity as a Relevant Phenotype in Mouse Models of Rare Disease

Image
Zoë Bichler, PhD - The Jackson Laboratory
Image
Image
Maximiliano Presa, PhD - The Jackson Laboratory
Image
The Jackson Laboratory will introduce their Neurobehavior Phenotyping Core, in which they also do visual acuity measurements. They will present two examples where the OptoDrum has been used to characterizte vision in animal models for rare disease: The Charcot-Marie-Tooth-disease, and Multiple-Sulfatase-Deficiency.
Featured image for “Journal Club: Measuring Visual Acuity and Contrast Sensitivity by Optomotor Reflex in Rodents”
Watch now
Thursday, 02 Apr 2020

Journal Club: Measuring Visual Acuity and Contrast Sensitivity by Optomotor Reflex in Rodents

Image
Dr. Thomas Münch - Striatech
Image
Image
Dr. Kaushikaram Subramanian - Max Planck Institute of Molecular Cell Biology and Genetics
Image
Image
Prof. Volker Enzmann - Department of Ophthalmology, University of Bern
Image
In vision research, observing the optomotor reflex (OMR) is an important and widely established method for assessing visual acuity and contrast sensitivity in rodents. In this event, we will hear about several applications of OMR measuremnts, ranging from quantification of retinal degeneration to characterization of night vision.
Keep exploring

Related application areas, neighbouring research chapters, and the questions researchers ask most.

Application Area

Retinal Degeneration

Progressive, largely irreversible loss of photoreceptors, RPE, and retinal ganglion cells across inherited, age-related, toxic, ischaemic, and inflammatory contexts. A cross-cutting mechanistic theme rather than a single disease entity.

10
Research Chapters
5
FAQs answered
Main Field where Retinal Degeneration is studied
Retinal Degeneration and Inherited Retinal Disease
Other relevant fields
Glaucoma and Optic Nerve Neurodegeneration
Maintaining and Restoring Vision
Neurodegenerative Disease: Alzheimer’s, Parkinson’s and Beyond
Neurodevelopment and Circuit Mechanisms
Neuroinflammation and Autoimmune CNS Disease
Ocular and CNS Toxicity Models
Rare and Inherited CNS and Eye Disorders
Systemic Aging and CNS decline
Vascular and Metabolic Disease: Diabetic Retinopathy and Stroke